Standard Adjuvant ET

Phase 3Small molecule

Eli Lilly

Standard Adjuvant ET is one of 84 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Chronic RhinosinusitisActive, not recruiting

Breast CancerActive, not recruiting

Allergic RhinitisPhase 3

Active, not recruiting

Chronic RhinosinusitisPhase 3

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tykerb

GSK

Preclinical

80 2

Standard Adjuvant ET

Eli Lilly

Phase 3

1 3

Avastin

Prolia

14 5

Voltaren

Novartis

Preclinical

1 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 9

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 10

Lipegfilgrastim

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)

NCT06338995

Q4 2028

Phase 3Recruiting

Allergic Rhinitis

NCT06339008

Clinical

Trials by Indication[1]

Breast Cancer1 trial

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Terminated· Eli Lilly logo

Eli Lilly·Phase 3·NCT04752332·111 enrolled

Allergic Rhinitis1 trial

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06339008·450 enrolled

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants With Chronic Rhinosinusitis With Nasal Polyps on Background Intranasal Corticosteroids

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06338995·510 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Standard Adjuvant ET. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard Adjuvant ET compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard Adjuvant ET. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Standard Adjuvant ET

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Trials by Indication[1]

Breast Cancer1 trial

Allergic Rhinitis1 trial

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

References

Drug Info

Quick Facts

Related News